Citadel Advisors’s Juniper Pharmaceuticals, Inc. Common Stock JNP Stock Holding History

Citadel Advisors’s Portfolio JNP Stock Details JNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-13,600	Closed	-$118K	–	10077
2018 Q2	$118K	Buy	13,600 +400	+3%	+$3.6K	﹤0.01%	8172
2018 Q1	$134K	Buy	+13,200	New	+$111K	﹤0.01%	7601

Citadel Advisors's JNP Position: Q3 2018 in Review

Citadel Advisors sold out of Juniper Pharmaceuticals, Inc. Common Stock (JNP) in Q3 2018, closing a stake of 13,635 shares — an estimated $119K sold.

Citadel Advisors first reported a position in JNP in Q1 2014 and held it in 4 quarters. The position peaked at $119K in Q2 2018. 0 funds tracked by Wall St. Rank hold JNP as of Q3 2018.

Citadel Advisors reported no remaining Juniper Pharmaceuticals, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
Citadel Advisors sold 13,635 Juniper Pharmaceuticals, Inc. Common Stock shares in Q3 2018, an estimated $119K.
Citadel Advisors first reported a position in Juniper Pharmaceuticals, Inc. Common Stock in Q1 2014 and held it in 4 quarters.
Citadel Advisors's Juniper Pharmaceuticals, Inc. Common Stock position peaked at $119K in Q2 2018.
0 funds tracked by Wall St. Rank held Juniper Pharmaceuticals, Inc. Common Stock as of Q3 2018.

Based on Citadel Advisors's 13F filing for Q3 2018, filed 13 Nov 2018.